Gideon Kapan
Founder & CEO
The company
Spectants’ research lab started in Strasbourg in 2023.
Our company brings together a multidisciplinary team of experts in biochemistry, biophysics, electrochemistry and biosensor design.
Laying the foundation for a new way to measure biomarkers at point of care.
From lab to market
-
2023
Lab Establishment
- Based in Strasbourg area
- First fundraising round
- Recruitment and equipment
-
2024
Development
- Sensor and reader prototyping
- Surface modification development
- First microfluidic system
-
2025
Optimization
- Sensor development
- Wafer level design and testing
- Proprietary algorithm for signal acquisition and analysis
- IP filing
-
2026
Prototyping
- B2X platform
- Second reader prototype
- A single‑use cartridge with integrated microfluidic filtering
- Laboratory validation
-
2027
Feasibility and Validation
- ISO and QMS
- Clinical validation
- Filing for UKCA conformity
- Preparation for CE/FDA
The Team
Gloria Volohonsky
CTO
David El Beze
Head of AI & DSP
R&D
Hélène Meyer
Head of Biochemistry
R&D
Mushka Javen
HR & Office Manager
Operations
Micha Ben Shem
Scientific Advisor
R&D
External consultants
Florian George
CFO
ROI & Risk Management
Yossi Zur
Product Designer
Mechanical Design
Robert Spieler
Head of Electronics
Analog/Digital & FPGA
Bob Roopra
Commercial Advisor
UK Market Development
Co-founders
Strategic board
Partnering
Ways to collaborate with us
Strategic Partnership
Long-term alliances with diagnostics and pharma leaders
Co-Development
Joint development of new assays, panels, or other IVD applications
Life Science Research
Use the B2X platform to study your target biomarker
Clinical Research
Become a study site for analytical and clinical validation
Technology Licensing
License the B2X platform for your own targets and applications
In collaboration with
(opens in a new tab)
(opens in a new tab)
(opens in a new tab)
(opens in a new tab)
(opens in a new tab)
